- The
two new patents are related to certain cannabinoid-infused beverage
compositions using LXRP’s DehydraTECH technology
- Globally,
LXRP has filed some 50 patent applications as the company expands its IP
portfolio; LXRP hopes to receive two more granted patents from Australia
by year end, giving it 12 in total
- LXRP
out-licenses its technology, which promotes healthier and faster
ingestion; the company seeks accelerated patent application examinations
in Australia based on the U.S. patents
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has been
granted two new U.S. patents based on cannabinoid-infused beverage compositions
using its DehydraTECH ingestion technology platform. The company is building
its strategic intellectual property (IP) portfolio with over 50 applications
worldwide and is seeking expedited examination for two more patents in
Australia based on the U.S. patents it received. It hopes to be granted two new
corresponding Australian patents by year’s end (http://ibn.fm/JOlXg).
If all are issued, LXRP will then hold 12 issued patents
within its first patent family, “Food and Beverage Compositions Infused With
Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen
LXRP’s IP claims in both countries. The two new U.S. patents granted are
numbers 10,103,225 and 10,084,044.
Based in British Columbia, Canada, LXRP is a biotechnology
company that has developed technology which has proven faster and more
effective delivery of cannabinoids in human clinical studies and nicotine in
animal laboratory studies. Its IP portfolio already includes patents for oral
delivery of all cannabinoids. The newest patents are to protect LXRP’s
cannabinoid-infused beverage compositions. The compositions use both
non-psychoactive cannabinoids, such as CBD, and also psychoactive cannabinoids,
such as THC.
LXRP has a growing IP portfolio and will license in any of
the countries worldwide where its technology already has a patent or is
patent-pending. DehydraTECH is its proprietary absorption technology platform.
LXRP has now filed a total of more than 50 patent
applications across 10 current patent families. It is preparing applications
for at least six more patents that will each form the basis for a separate patent
family. It expects to file them before the end of this year, giving it
management over a total of 16 patent families. The company anticipates that
numerous patents will be granted within each of these families (http://ibn.fm/NMrUd).
For more information, visit the company’s website at www.LexariaBioscience.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment